stockrow
Friday 6 November 2026
Export BVS’s income statement to Excel — free account
Bioventus Inc.
BVS Healthcare Medical Devices
Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024.
- Revenue
- +2.73%
- EPS
- +100.6%
- Free cash flow
- −31.4%
- Total debt
- −28.8%
Quarter to September 2026, against a year earlier
10.68
0.00
0.00%
Follow BVS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
21.88 | 21.23 | 11.65 | 15.84 |
P/S ratio |
0.87 | 1.07 | 1.10 | 1.59 | |
P/FCF ratio |
6.87 | 6.11 | 6.80 | 10.97 | |
P/Operating CF |
13.06 | 68.77 | 32.24 | 45.11 | |
P/B ratio |
2.17 | 2.62 | 2.31 | 3.19 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.30 | 1.48 | 1.48 | 1.93 | |
EV/EBITDA |
7.31 | 8.19 | 8.30 | 11.21 | |
EV/Operating CF |
9.89 | 8.26 | 8.87 | 12.94 | |
EV/FCF |
10.24 | 8.45 | 9.12 | 13.31 | |
Quick Ratio |
1.12 | 1.06 | 1.10 | 1.07 | |
Current Ratio |
1.70 | 1.69 | 1.69 | 1.68 | |
Net Debt/EBITDA |
7.78 | 12.04 | 7.28 | 9.95 | |
Debt/Assets |
43.00% | 41.82% | 36.90% | 34.13% | |
Debt/Equity |
1.29 | 1.16 | 0.90 | 0.79 | |
Asset Turnover |
0.80 | 0.86 | 0.84 | 0.85 | |
Operating CF/Net income |
2.57 | 2.87 | 0.59 | 3.45 | |
Capex/Depreciation |
(0.05) | (0.05) | (0.09) | (0.03) | |
Interest Coverage |
3.67 | 1.95 | 4.70 | 2.58 | |
Research and Development Expense of Revenue |
1.90% | 1.87% | 2.07% | 2.41% | |
Selling, General and Administrative Expense of Revenue |
52.41% | 59.30% | 54.01% | 58.23% | |
Intangible Assets out of Total Assets |
0.55 | 0.56 | 0.53 | 0.52 | |
Share Based Compensation of Revenue |
2.18% | 2.47% | 3.29% | 3.34% | |
Graham Net Nets |
(0.37) | (0.27) | (0.22) | (0.12) | |
Graham Number |
5.12 | 5.80 | 8.63 | 9.09 | |
Earnings Yield |
4.57% | 4.71% | 8.58% | 6.31% | |
Free Cash Flow Yield |
14.55% | 16.38% | 14.72% | 9.12% | |
Revenue per Share |
2.37 | 1.96 | 2.26 | 2.08 | |
Operating CF per Share |
0.57 | 0.13 | 0.29 | 0.30 | |
Capex per Share |
(0.01) | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
0.56 | 0.12 | 0.28 | 0.30 | |
Cash per Share |
0.77 | 0.53 | 0.43 | 0.45 | |
Shareholders Equity per Share |
3.43 | 3.48 | 4.09 | 4.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.43 | 3.48 | 4.09 | 4.27 | |
Free Cash Flow |
37.39 | 8.36 | 18.91 | 20.32 | |
Working Capital |
112.46 | 101.72 | 105.08 | 107.84 | |
Capital Expenditures |
(0.58) | (0.57) | (0.96) | (0.33) | |
Net Current Asset Value |
(182.27) | (166.46) | (138.41) | (116.01) | |
EV/EBIT |
13.68 | 14.79 | 14.75 | 19.94 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.00 | |
Price to Operating Income |
9.18 | 10.68 | 10.99 | 16.43 | |
| Other line items | |||||
Average Receivables |
127.85 | 119.30 | 135.39 | 134.32 | |
Average Payables |
17.31 | 21.62 | 22.22 | 26.22 | |
Average Inventory |
87.36 | 88.62 | 88.14 | 89.68 | |
Average Assets |
705.76 | 670.98 | 690.07 | 687.51 | |
Average Common Equity |
207.03 | 209.87 | 239.36 | 249.56 |
Columns are period end dates · fundamentals updated 5 Nov 2026